1. Home
  2. PCVX vs CNS Comparison

PCVX vs CNS Comparison

Compare PCVX & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCVX
  • CNS
  • Stock Information
  • Founded
  • PCVX 2013
  • CNS 1986
  • Country
  • PCVX United States
  • CNS United States
  • Employees
  • PCVX N/A
  • CNS N/A
  • Industry
  • PCVX Biotechnology: Pharmaceutical Preparations
  • CNS Investment Managers
  • Sector
  • PCVX Health Care
  • CNS Finance
  • Exchange
  • PCVX Nasdaq
  • CNS Nasdaq
  • Market Cap
  • PCVX 4.4B
  • CNS 4.0B
  • IPO Year
  • PCVX 2020
  • CNS 2004
  • Fundamental
  • Price
  • PCVX $36.24
  • CNS $76.30
  • Analyst Decision
  • PCVX Strong Buy
  • CNS Hold
  • Analyst Count
  • PCVX 10
  • CNS 3
  • Target Price
  • PCVX $136.50
  • CNS $82.00
  • AVG Volume (30 Days)
  • PCVX 1.5M
  • CNS 248.7K
  • Earning Date
  • PCVX 08-05-2025
  • CNS 07-17-2025
  • Dividend Yield
  • PCVX N/A
  • CNS 3.24%
  • EPS Growth
  • PCVX N/A
  • CNS 23.33
  • EPS
  • PCVX N/A
  • CNS 3.15
  • Revenue
  • PCVX N/A
  • CNS $543,579,000.00
  • Revenue This Year
  • PCVX N/A
  • CNS $6.76
  • Revenue Next Year
  • PCVX N/A
  • CNS $10.52
  • P/E Ratio
  • PCVX N/A
  • CNS $24.35
  • Revenue Growth
  • PCVX N/A
  • CNS 11.54
  • 52 Week Low
  • PCVX $27.66
  • CNS $68.99
  • 52 Week High
  • PCVX $121.06
  • CNS $110.67
  • Technical
  • Relative Strength Index (RSI)
  • PCVX 55.76
  • CNS 51.07
  • Support Level
  • PCVX $35.25
  • CNS $72.05
  • Resistance Level
  • PCVX $37.95
  • CNS $78.72
  • Average True Range (ATR)
  • PCVX 1.54
  • CNS 2.18
  • MACD
  • PCVX 0.14
  • CNS -0.05
  • Stochastic Oscillator
  • PCVX 72.24
  • CNS 62.87

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.

Share on Social Networks: